Literature DB >> 1708933

Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.

D C Montefiori1, I Y Zhou, B Barnes, D Lake, E M Hersh, Y Masuho, L B Lefkowitz.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) exhibits extensive genomic and antigenic diversity, which is thought to contribute to the failure of the host's immune response to control infection and prevent clinical progression. Part of this failure may be due to utilization by the virus of antigenic variation as a means to escape protective immune responses. Antibody-escape variants of HIV-1 were studied here using fresh clinical isolates and autologous plasmas. HIV-1 was isolated from the plasma of seven people who were all seropositive for at least 2 years, and symptomatic sometime during that period. Isolated viruses were confirmed as HIV-1 by the presence of reverse transcriptase activity in infected culture supernatants, and by positive immunofluorescence using human monoclonal antibody to HIV-1 core protein. Plasma from these people were positive by Western immunoblot (DuPont) for most major HIV-1 (strain IIIB) antigens. These plasmas neutralized three laboratory strains of HIV-1 (i.e., IIIB, RF, and MN) but did not neutralize the homotypic strain in five cases, and had greatly reduced neutralizing titers against the homotypic strain in two cases. Homotypic neutralizing antibodies were absent in autologous plasma obtained 3 months later. When antibody titers were measured by fixed-cell indirect immunofluorescence assays (IFAs), high titers of IgG (1:6400 to 1:25,600) were detected against HIV-1 IIIB, while low titers of only 1:20 to 1:160 were detected against homotypic viral antigens at the time of virus isolation, and remained low 12 and 16 weeks later. No class IgA, IgD, IgE, or IgM antibodies to homotypic viral antigens, as possible IgG-blocking antibodies, were detected by fixed-cell IFAs. Cross-reactions with heterologous donor's plasmas were observed in some cases, and in these cases the cross-reactions were unidirectional. Live-cell IFAs detected IgG in patient's plasma to HIV-1 IIIB-infected cells but not to cells infected with homotypic isolates. These results suggest that it is common for neutralization-resistant HIV-1 variants to appear during the course of infection, and that all or most antigens of these variants are capable of escaping antibody recognition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708933     DOI: 10.1016/0042-6822(91)90604-a

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

Review 1.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys.

Authors:  David H Margolin; Erika F Helmuth Saunders; Benjamin Bronfin; Nicole de Rosa; Michael K Axthelm; Xavier Alvarez; Norman L Letvin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Authors:  Rebecca M Lynch; Patrick Wong; Lillian Tran; Sijy O'Dell; Martha C Nason; Yuxing Li; Xueling Wu; John R Mascola
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

4.  Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Authors:  Masashi Shingai; Olivia K Donau; Stephen D Schmidt; Rajeev Gautam; Ronald J Plishka; Alicia Buckler-White; Reza Sadjadpour; Wendy R Lee; Celia C LaBranche; David C Montefiori; John R Mascola; Yoshiaki Nishimura; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

5.  Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.

Authors:  J S McDougal; M S Kennedy; S L Orloff; J K Nicholson; T J Spira
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

8.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 9.  HIV-1 neutralizing antibodies: understanding nature's pathways.

Authors:  John R Mascola; Barton F Haynes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  The cat and mouse of HIV-1 antibody escape.

Authors:  John R Mascola
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.